It’s best to be first, but drugs that are approved later with the same mechanism of action can also create significant value for patients and society by being best-in-class (BIC), or what clinicians refer to as “gold standard.” Recently we highlighted key factors that can make a follow-on drug be considered a best-in-class drug. This article provides ten historical case studies of best-in-class drug strategies across therapeutic indications.
Case Studies of Best-in-Class (BIC) Drugs:
The following case studies (1-3 for therapeutic superiority, 4-6 for improved safety and 7-10 for improving patient acceptance/lowering treatment burden) explore in more detail how a drug can create more value to become considered best-in-class:
get free samples and a Premium trial
Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: